120 related articles for article (PubMed ID: 28261513)
1. Primary Clear Cell Microcystic Adenoma of the Sinonasal Cavity: Pathological or Fortuitous Association?
Cooper R; Markham H; Theaker J; Bateman A; Bunyan D; Sommerlad M; Crawford G; Eccles D
Case Rep Pathol; 2017; 2017():9236780. PubMed ID: 28261513
[TBL] [Abstract][Full Text] [Related]
2. A von Hippel-Lindau disease-associated microcystic adenoma of the ethmoid sinus: case report.
Xu DS; Dirks MS; Quezado MM; Lubensky IA; Zhuang Z; Lonser RR; Asthagiri AR
Neurosurgery; 2011 Oct; 69(4):E1017-21; discussion E1021-2. PubMed ID: 21572360
[TBL] [Abstract][Full Text] [Related]
3. A Von Hippel-Lindau Disease-Associated Microcystic Adenoma of the Ethmoid Sinus Mimicking Metastatic Clear Cell Renal Cell Carcinoma.
Tsukamoto S; Koyasu S; Sugimoto A; Matsunaga M; Nakamoto Y
Clin Nucl Med; 2023 Feb; 48(2):194-196. PubMed ID: 36179325
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours.
Crossey PA; Foster K; Richards FM; Phipps ME; Latif F; Tory K; Jones MH; Bentley E; Kumar R; Lerman MI
Hum Genet; 1994 Jan; 93(1):53-8. PubMed ID: 8270255
[TBL] [Abstract][Full Text] [Related]
5. Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
Batavia AA; Schraml P; Moch H
Histopathology; 2019 Jan; 74(1):60-67. PubMed ID: 30565303
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.
Maher ER; Webster AR; Richards FM; Green JS; Crossey PA; Payne SJ; Moore AT
J Med Genet; 1996 Apr; 33(4):328-32. PubMed ID: 8730290
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
9. Von Hippel-Lindau disease and endocrine tumour susceptibility.
Woodward ER; Maher ER
Endocr Relat Cancer; 2006 Jun; 13(2):415-25. PubMed ID: 16728571
[TBL] [Abstract][Full Text] [Related]
10. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
[TBL] [Abstract][Full Text] [Related]
11. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.
Gläsker S; Bender BU; Apel TW; Natt E; van Velthoven V; Scheremet R; Zentner J; Neumann HP
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):758-62. PubMed ID: 10567493
[TBL] [Abstract][Full Text] [Related]
12. Benefits of screening in von Hippel-Lindau disease--comparison of morbidity associated with initial tumours in affected parents and children.
Priesemann M; Davies KM; Perry LA; Drake WM; Chew SL; Monson JP; Savage MO; Johnston LB
Horm Res; 2006; 66(1):1-5. PubMed ID: 16651847
[TBL] [Abstract][Full Text] [Related]
13. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of Von Hippel-Lindau (VHL) disease.
Hes FJ; van der Luijt RB; Lips CJ
Neth J Med; 2001 Nov; 59(5):225-34. PubMed ID: 11705642
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic analysis of von Hippel-Lindau disease.
Richards FM; Webster AR; McMahon R; Woodward ER; Rose S; Maher ER
J Intern Med; 1998 Jun; 243(6):527-33. PubMed ID: 9681854
[TBL] [Abstract][Full Text] [Related]
17. Adrenal adenoma in von Hippel-Lindau syndrome: A case report with review of literature.
Palui R; Kamalanathan S; Sahoo J; Dorairajan LN; Badhe B; Gochhait D
J Cancer Res Ther; 2019 Mar; 15(Supplement):S163-S166. PubMed ID: 30900640
[TBL] [Abstract][Full Text] [Related]
18. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
Alleman WG; Tabios RL; Chandramouli GV; Aprelikova ON; Torres-Cabala C; Mendoza A; Rogers C; Sopko NA; Linehan WM; Vasselli JR
Clin Cancer Res; 2004 Oct; 10(20):7011-21. PubMed ID: 15501981
[TBL] [Abstract][Full Text] [Related]
19. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas.
Kim SG; Wu TT; Lee JH; Yun YK; Issa JP; Hamilton SR; Rashid A
Mod Pathol; 2003 Nov; 16(11):1086-94. PubMed ID: 14614047
[TBL] [Abstract][Full Text] [Related]
20. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.
Vortmeyer AO; Lubensky IA; Fogt F; Linehan WM; Khettry U; Zhuang Z
Am J Pathol; 1997 Oct; 151(4):951-6. PubMed ID: 9327728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
